 |
 |
from: WE-MOVE news Subject: PD: Proteasome Inhibition, Valve Disease, Testosterone Saturday, August 21, 2004 Issue 39 VOLUME 1 ISSUE 39 http://www.imakenews.com/wemove/index000059443.cfm ------------------------------------------------------------------------- ----- Systemic Proteasome Inhibitors Replicate Key Features of PD Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease KSP McNaught, DP Perl, AL Brown, CW Olanow Ann Neurol 2004;56:149-162 A new model of PD strengthens the case that proteasome inhibtion is a major step in the pathogenesis of Parkinson's disease. http://www.imakenews.com/wemove/e_article000294702.cfm?x=b3r0fdN,b1Qs8yH9 More Valvular Heart Disease from Ergot-Derived Dopamine Agonists Two new studies report six new cases of valvular heart disease from ergot-derived dopmaine agonists. Horvath et al. urge "an assessment of cardiac function be performed before and in the course of long-term therapy with ergot derivative dopamine agonists," and Agarwal recommend not using these agents as first-line dopamine agonists. http://www.imakenews.com/wemove/e_article000294703.cfm?x=b3r0fdN,b1Qs8yH 9 Apathy and Testosterone; Sexuality After DBS in PD One new study shows a correlation between low testosterone and apathy in male PD patients, while another shows that sexual well being after STN DBS surgery is unchanged in women, and only slightly improved in men. http://www.imakenews.com/wemove/e_article000294704.cfm?x=b3r0fdN,b1Qs8yH9 Judith Blazer, Executive Director WE MOVE Edited by Richard Robinson, WE MOVE ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn